France-based Tollys SAS has raised €2.3 million to advance the preclinical development of its lead cancer immunotherapy, bringing the total amount raised to €6.4 million since the company was founded in 2015. The Series A financing round followed the achievement of preclinical proof-of-concept for the candidate drug TL-532.
